Recommended

New webinar with Fujifilm: Monocyte activation test (MAT): Insight into examining regulations and markets prospects
New webinar: The path to optimisation in pharmaceutical microbiology
Join our webinar: An alternative medium to support sterility testing using the Growth Direct® Rapid Sterility System
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps
news

Drugmakers may use Purdue’s bankruptcy to settle opioid suits

Drugmakers that face litigation over the opioid crisis are looking at ways to settle the cases by using Purdue’s bankruptcy, it has been reported.

It has been reported that Endo International Plc, Johnson & Johnson and other drugmakers that face litigation over the opioid crisis are exploring a way to settle the cases by participating in Purdue Pharma LP’s bankruptcy.

Five drugmakers battling the cases (Endo, J&J, Teva Pharmaceutical Industries Ltd , Allergan Plc and Mallinckrodt Plc) are looking to enact a global settlement of the litigation that would be implemented through Purdue’s Chapter 11 case, the Wall Street Journal has reported.

According to the report, the mechanism, if successful, would allow the companies to contribute money into a trust set up through the bankruptcy in exchange for a complete release from liability.

Purdue Pharma filed for bankruptcy protection back in September after a settlement offer from the company over the opioid crisis was rejected by 24 states.

Johnson & Johnson was ordered to pay $572 million to Oklahoma over the opioid crisis back in August, whilst Teva agreed on an $85 million settlement for the opioid epidemic case in Oklahoma in May. Endo and Allergan agreed to pay $15 million to certain Ohio counties before the opioid abuse case went to trial.